Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Mirvetuximab soravtansine by ImmunoGen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Mirvetuximab soravtansine is under clinical development by ImmunoGen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Data Insights
Mirvetuximab soravtansine by ImmunoGen for Endometrial Cancer: Likelihood of Approval
Mirvetuximab soravtansine is under clinical development by ImmunoGen and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...